<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002867" GROUP_ID="PREG" ID="927400010412092184" MERGED_FROM="" MODIFIED="2008-02-20 13:26:04 +0100" MODIFIED_BY="Sonja Henderson" NOTES="&lt;p&gt;Exported from Review Manager 4.2&lt;br&gt;Exported from Review Manager 4.3&lt;br&gt;Exported from Review Manager 4.2&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Short title (no longer in use): Treatment for Secondary Postpartum Haemorrhage.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-02-14 13:56:16 +0000" NOTES_MODIFIED_BY="Sonja Henderson" REVIEW_NO="0257" REVMAN_SUB_VERSION="5.0.0 release candidate 3" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2008-02-20 13:26:04 +0100" MODIFIED_BY="Sonja Henderson">
<TITLE>Treatments for secondary postpartum haemorrhage</TITLE>
<CONTACT MODIFIED="2008-02-20 13:26:04 +0100" MODIFIED_BY="Sonja Henderson"><PERSON ID="15824" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Jo</FIRST_NAME><LAST_NAME>Alexander</LAST_NAME><POSITION>Professor of Midwifery Research and Development</POSITION><EMAIL_1>jalexand@bournemouth.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>School of Health and Social Care</DEPARTMENT><ORGANISATION>Bournemouth University</ORGANISATION><ADDRESS_2>Christchurch Road</ADDRESS_2><CITY>Bournemouth</CITY><ZIP>BH1 3LG</ZIP><REGION>Dorset</REGION><COUNTRY CODE="">UK</COUNTRY><PHONE_1>+44 1202 967360</PHONE_1><FAX_1>+44 1202 967326</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-02-20 13:26:04 +0100" MODIFIED_BY="Sonja Henderson"><PERSON ID="15824" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Jo</FIRST_NAME><LAST_NAME>Alexander</LAST_NAME><POSITION>Professor of Midwifery Research and Development</POSITION><EMAIL_1>jalexand@bournemouth.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>School of Health and Social Care</DEPARTMENT><ORGANISATION>Bournemouth University</ORGANISATION><ADDRESS_2>Christchurch Road</ADDRESS_2><CITY>Bournemouth</CITY><ZIP>BH1 3LG</ZIP><REGION>Dorset</REGION><COUNTRY CODE="">UK</COUNTRY><PHONE_1>+44 1202 967360</PHONE_1><FAX_1>+44 1202 967326</FAX_1></ADDRESS></PERSON><PERSON ID="14878" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Peter</FIRST_NAME><MIDDLE_INITIALS>W</MIDDLE_INITIALS><LAST_NAME>Thomas</LAST_NAME><POSITION>Professor of Health Care Statistics and Epidemiology</POSITION><EMAIL_1>Peter.Thomas@poole.nhs.uk</EMAIL_1><ADDRESS><DEPARTMENT>Dorset Research and Development Support Unit</DEPARTMENT><ORGANISATION>Poole Hospital NHS Trust</ORGANISATION><ADDRESS_1>Cornelia House</ADDRESS_1><ADDRESS_2>Longfleet Road</ADDRESS_2><CITY>Poole</CITY><ZIP>BH15 2JB</ZIP><REGION>Dorset</REGION><COUNTRY CODE="">UK</COUNTRY><PHONE_1>+44 01202 448489</PHONE_1><FAX_1>+44 01202 448490</FAX_1></ADDRESS></PERSON><PERSON ID="16014" ROLE="AUTHOR"><FIRST_NAME>Jill</FIRST_NAME><LAST_NAME>Sanghera</LAST_NAME><POSITION>Midwifery Research Fellow</POSITION><EMAIL_1>jsanghera@bournemouth.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Institute of Health and Community Studies</DEPARTMENT><ORGANISATION>Bournemouth University</ORGANISATION><ADDRESS_1>Bournemouth House</ADDRESS_1><ADDRESS_2>Christchurch Road</ADDRESS_2><CITY>Bournemouth</CITY><ZIP>BH1 3LG</ZIP><REGION>Dorset</REGION><COUNTRY CODE="">UK</COUNTRY><PHONE_1>+44 1202 504244</PHONE_1><FAX_1>+44 1202 504326</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-02-14 13:31:17 +0000" MODIFIED_BY="Sonja Henderson" NOTES="&lt;p&gt;Minor update: 2/5/08&lt;/p&gt;&lt;p&gt;New studies found and included or excluded: 2/5/08&lt;/p&gt;" NOTES_MODIFIED="2008-02-14 13:31:17 +0000" NOTES_MODIFIED_BY="Sonja Henderson">
<UP_TO_DATE>
<DATE DAY="31" MONTH="1" YEAR="2008"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="31" MONTH="1" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="1" YEAR="2010"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2002"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2002"/>
</DATES>
<WHATS_NEW MODIFIED="2008-02-14 13:55:46 +0000" MODIFIED_BY="Sonja Henderson" NOTES="&lt;p&gt;February 2008&lt;br&gt;Search updated. One new trial identified (Grunberger 1983), translated, and excluded.&lt;/p&gt;" NOTES_MODIFIED="2008-02-14 13:55:46 +0000" NOTES_MODIFIED_BY="Sonja Henderson">
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="12" MONTH="2" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-02-14 13:55:46 +0000" MODIFIED_BY="Sonja Henderson">
<DATE DAY="31" MONTH="1" YEAR="2008"/>
<DESCRIPTION>
<P>Search updated. One new trial identified and excluded (<LINK REF="STD-Grunberger-1983" TYPE="STUDY">Grunberger 1983</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-02-14 13:31:36 +0000" MODIFIED_BY="Sonja Henderson"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>School of Health and Social Care, Bournemouth University</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Dorset Research and Development Support Unit, Poole Hospital</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-02-14 13:56:16 +0000" MODIFIED_BY="Sonja Henderson">
<SUMMARY MODIFIED="2008-02-12 14:28:18 +0000" MODIFIED_BY="Denise Atherton">
<TITLE MODIFIED="2008-02-12 14:28:18 +0000" MODIFIED_BY="Denise Atherton">Treatments for secondary postpartum haemorrhage</TITLE>
<SUMMARY_BODY MODIFIED="2008-02-12 14:28:03 +0000" MODIFIED_BY="Denise Atherton">
<P>No randomised controlled trials to inform the management of women with secondary postpartum haemorrhage</P>
<P>Sometimes women experience abnormal or excessive bleeding from the birth canal between 24 hours and 12 weeks after giving birth, and this is called secondary postpartum haemorrhage. It is usually caused by a tear, an infection, or by fragments of the placenta or membranes, or both, remaining in the uterus and causing infection or preventing the uterus from contracting. It can be painful, disruptive to daily life with a new baby and can exacerbate extreme tiredness. Although the specific incidence is not known, in low-income countries it is probably a serious cause of maternal mortality. In high-income countries, about 2% of women are admitted to hospital with this condition. Treatments may include giving drugs to treat infection and/or control bleeding and/or a variety of surgical procedures. Studies could have compared an individual treatment to another, combinations of treatments to others, and any individual or combination of treatments to either a placebo or no treatment group. However, no trials were identified and so there is no good evidence on which to base guidance. A well-designed trial is needed.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-02-14 13:39:56 +0000" MODIFIED_BY="Sonja Henderson">
<ABS_BACKGROUND MODIFIED="2008-02-14 13:34:29 +0000" MODIFIED_BY="Sonja Henderson">
<P>Secondary postpartum haemorrhage is any abnormal or excessive bleeding from the birth canal occurring between 24 hours and 12 weeks postnatally. In developed countries, 2% of postnatal women are admitted to hospital with this condition, half of them undergoing uterine surgical evacuation. Data are not available from developing countries.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To evaluate the relative effectiveness and safety of the treatments used for secondary postpartum haemorrhage.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-02-12 13:44:27 +0000" MODIFIED_BY="Denise Atherton">
<P>We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (31 January 2008), the reference lists of trial reports and reviews and sought further sources from the first named authors of the papers identified.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All randomised or quasi-randomised comparisons between drug therapies, surgical therapies and placebo or no treatment for the management of secondary postpartum haemorrhage occurring between 24 hours and three months following a pregnancy of at least 24 weeks' gestation. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2008-02-14 13:33:31 +0000" MODIFIED_BY="Sonja Henderson">
<P>Two authors scrutinised reports of possibly eligible studies. The third author acted as an advisor or arbitrator.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-02-14 13:39:56 +0000" MODIFIED_BY="Sonja Henderson">
<P>Of the 47 papers (36 studies) identified, none met the inclusion criteria.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>No information is available from randomised controlled trials to inform the management of women with secondary postpartum haemorrhage. This topic may have received little attention because it is perceived as being associated with maternal morbidity rather than mortality in developed countries; it is only recently that the extent and importance of postnatal maternal morbidity has been recognised. A well-designed randomised controlled trial comparing the various therapies for women with secondary postpartum haemorrhage against each other and against placebo or no treatment groups is needed.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-02-14 13:56:16 +0000" MODIFIED_BY="Sonja Henderson">
<BACKGROUND MODIFIED="2008-02-14 13:38:02 +0000" MODIFIED_BY="Sonja Henderson">
<P>Secondary postpartum haemorrhage is defined as any abnormal or excessive bleeding from the birth canal occurring between 24 hours (<LINK REF="REF-Dewhurst-1966" TYPE="REFERENCE">Dewhurst 1966</LINK>) and 12 weeks (<LINK REF="REF-Rome-1975" TYPE="REFERENCE">Rome 1975</LINK>) postnatally and, as this definition includes no reference to the volume of blood loss or the condition of the woman, the spectrum of the condition can vary from inconvenient to fatal. However, in developed countries around 1% of postnatal women undergo surgical uterine evacuation (evacuation of retained products of conception) for secondary postpartum haemorrhage (<LINK REF="REF-ACOG-1990" TYPE="REFERENCE">ACOG 1990</LINK>; <LINK REF="REF-Dewhurst-1966" TYPE="REFERENCE">Dewhurst 1966</LINK>; <LINK REF="REF-Glazener-1999" TYPE="REFERENCE">Glazener 1999</LINK>) and a further 1% are admitted to hospital but managed conservatively (<LINK REF="REF-Alexander-1997" TYPE="REFERENCE">Alexander 1997</LINK>; <LINK REF="REF-Glazener-1999" TYPE="REFERENCE">Glazener 1999</LINK>). Leaving aside any physical morbidity, it is generally acknowledged that the postnatal period is a time of significant psychological upheaval for women and their families even without the added disruption of needing medical treatment and possibly admission to, or extra time in, hospital (<LINK REF="REF-Raphael_x002d_Leff-1991" TYPE="REFERENCE">Raphael-Leff 1991</LINK>). Secondary postpartum haemorrhage is, however, a topic that has received little attention because it is perceived as being associated with maternal morbidity rather than mortality in developed countries (<LINK REF="REF-King-1989" TYPE="REFERENCE">King 1989</LINK>); it is only relatively recently that the importance of postnatal maternal morbidity has been recognised (<LINK REF="REF-MacArthur-1991" TYPE="REFERENCE">MacArthur 1991</LINK>). It seems likely that this morbidity may include anaemia, which would be worsened by secondary postpartum haemorrhage, and serve to add to the extreme tiredness that many postnatal women experience (<LINK REF="REF-Bick-1995" TYPE="REFERENCE">Bick 1995</LINK>).</P>
<P>Secondary postpartum haemorrhage, which appears frequently to be linked with genital tract infection, still results in maternal death in developed countries albeit very occasionally. In the UK, one maternal death occurred due to secondary postpartum haemorrhage between 1994 and 1996 (<LINK REF="REF-DoH-1999" TYPE="REFERENCE">DoH 1999</LINK>), but none between 2000 and 2002 (<LINK REF="REF-CEMACH-2004" TYPE="REFERENCE">CEMACH 2004</LINK>). It seems likely that related maternal deaths are more common in developing countries, but data do not appear to be available.</P>
<P>If secondary postpartum haemorrhage is sufficiently severe to result in admission to hospital, treatment usually falls into two broad categories: drug treatment or surgery, or both (<LINK REF="REF-Alexander-1997" TYPE="REFERENCE">Alexander 1997</LINK>; <LINK REF="REF-Weisenberg_x002d_Smith1993" TYPE="REFERENCE">Weisenberg-Smith1993</LINK>). The rationale for these treatments appears to be that the uterus has failed to contract adequately to prevent bleeding from the placental site, the underlying cause of this being retained products or intrauterine infection, or both (<LINK REF="REF-Crowley-1984" TYPE="REFERENCE">Crowley 1984</LINK>; <LINK REF="REF-King-1989" TYPE="REFERENCE">King 1989</LINK>; <LINK REF="REF-Rome-1975" TYPE="REFERENCE">Rome 1975</LINK>). However, the underlying cause of the condition is often not established. Drug therapy consists of oxytocics or antibiotics, or both; hormonal preparations may also be given to regulate bleeding (<LINK REF="REF-RCOG-1994" TYPE="REFERENCE">RCOG 1994</LINK>). Antibiotic regimens used for endometritis (inflammation of the lining of the womb causing pain) after delivery are the subject of a separate review (<LINK REF="REF-French-2004" TYPE="REFERENCE">French 2004</LINK>) but clearly endometritis and secondary postpartum haemorrhage are not mutually exclusive conditions. Surgery might involve evacuation of retained products (<I>see</I> above), cervical dilatation, repair of cervical tear or uterine rupture, molar pregnancy treatment and, rarely, hysterectomy.</P>
<P>There is evidence to suggest that endometritis is increased among women who have prelabour rupture of membranes at term (<LINK REF="REF-Novak_x002d_Antolic-1997" TYPE="REFERENCE">Novak-Antolic 1997</LINK>) or who are delivered by caesarean section (<LINK REF="REF-Calhoun-1995" TYPE="REFERENCE">Calhoun 1995</LINK>; <LINK REF="REF-Milligan-1992" TYPE="REFERENCE">Milligan 1992</LINK>; <LINK REF="REF-Stovall-1998" TYPE="REFERENCE">Stovall 1998</LINK>). Events in the immediately preceding pregnancy, which have been suggested as predisposing a woman to secondary postpartum haemorrhage, are the mother smoking at the time the antenatal history was taken (<LINK REF="REF-Marchant-2006" TYPE="REFERENCE">Marchant 2006</LINK>); multiple pregnancy (<LINK REF="REF-King-1989" TYPE="REFERENCE">King 1989</LINK>; <LINK REF="REF-Thorsteinsson-1970" TYPE="REFERENCE">Thorsteinsson 1970</LINK>); threatened miscarriage (<LINK REF="REF-Marchant-2006" TYPE="REFERENCE">Marchant 2006</LINK>;<LINK REF="REF-Thorsteinsson-1970" TYPE="REFERENCE">Thorsteinsson 1970</LINK>); antepartum haemorrhage (<LINK REF="REF-Thorsteinsson-1970" TYPE="REFERENCE">Thorsteinsson 1970</LINK>); hospital admission during the third trimester (<LINK REF="REF-Marchant-2006" TYPE="REFERENCE">Marchant 2006</LINK>); precipitate labour of less than two hours (<LINK REF="REF-Thorsteinsson-1970" TYPE="REFERENCE">Thorsteinsson 1970</LINK>); the administration of intravenous ergometrine (0.5 mg) as preventative management for the third stage of labour (<LINK REF="REF-Begley-1990" TYPE="REFERENCE">Begley 1990</LINK>); prolonged third stage (<LINK REF="REF-Lester-1956" TYPE="REFERENCE">Lester 1956</LINK>; <LINK REF="REF-Marchant-2006" TYPE="REFERENCE">Marchant 2006</LINK>; <LINK REF="REF-Thorsteinsson-1970" TYPE="REFERENCE">Thorsteinsson 1970</LINK>); incomplete placenta or membranes passed at birth, or both (<LINK REF="REF-Dewhurst-1966" TYPE="REFERENCE">Dewhurst 1966</LINK>; <LINK REF="REF-Lester-1956" TYPE="REFERENCE">Lester 1956</LINK>; <LINK REF="REF-Marchant-2006" TYPE="REFERENCE">Marchant 2006</LINK>; <LINK REF="REF-Rome-1975" TYPE="REFERENCE">Rome 1975</LINK>; <LINK REF="REF-Thorsteinsson-1970" TYPE="REFERENCE">Thorsteinsson 1970</LINK>); primary postpartum haemorrhage (<LINK REF="REF-Rome-1975" TYPE="REFERENCE">Rome 1975</LINK>); and not breastfeeding (<LINK REF="REF-Marchant-2006" TYPE="REFERENCE">Marchant 2006</LINK>). A previous history of secondary postpartum haemorrhage predisposes to a recurrence (<LINK REF="REF-Dewhurst-1966" TYPE="REFERENCE">Dewhurst 1966</LINK>; <LINK REF="REF-Marchant-2006" TYPE="REFERENCE">Marchant 2006</LINK>; <LINK REF="REF-Thorsteinsson-1970" TYPE="REFERENCE">Thorsteinsson 1970</LINK>) and it has been suggested that it is more common amongst multiparous women (<I>see </I>
<LINK REF="REF-Glazener-1995" TYPE="REFERENCE">Glazener 1995</LINK>; <LINK REF="REF-King-1989" TYPE="REFERENCE">King 1989</LINK>).<BR/>
<BR/>There has been no systematic review to assess the relative effectiveness of treatments for secondary postpartum haemorrhage.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To evaluate the relative effectiveness and safety of the treatments used for secondary postpartum haemorrhage.</P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>All randomised comparisons between drug therapies, surgical therapies and placebo or no treatment for the management of secondary postpartum haemorrhage were eligible for inclusion. Quasi-randomised studies (for example, alternate allocation, allocation by hospital number, etc) were also eligible for inclusion.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Women from 24 hours to three months following a pregnancy of at least 24 weeks' gestation with a diagnosis of secondary postpartum haemorrhage. Any definition of secondary postpartum haemorrhage would have been accepted providing the criteria used were made clear within the paper concerned. Studies were eligible whatever the location in which treatment was received and whatever the length of the follow up.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>There are three types of drug treatment (antibiotics, oxytocics and hormone therapy) and a variety of surgical treatments. We would have assumed that variations in the effectiveness of drug treatments within these broad bands were not important (for example, different types of hormone therapy). Control groups could have been given placebo or no treatment. Potentially studies could have compared an individual treatment to another, combinations of treatments to others, and any individual or combination of treatments to either type of control group. All were of interest but specifically: <BR/>
</P>
<UL>
<LI>antibiotics versus oxytocics; </LI>
<LI>antibiotics versus hormone therapy; </LI>
<LI>antibiotics versus placebo; </LI>
<LI>antibiotics versus no treatment; </LI>
<LI>antibiotics and oxytocics versus hormone therapy; </LI>
<LI>antibiotics and hormone therapy versus oxytocics; </LI>
<LI>antibiotics and oxytocics versus placebo; </LI>
<LI>antibiotics and oxytocics versus no treatment; </LI>
<LI>antibiotics and hormone therapy versus placebo; </LI>
<LI>antibiotics and hormone therapy versus no treatment; </LI>
<LI>oxytocics versus hormone therapy; </LI>
<LI>oxytocics versus placebo;</LI>
<LI>oxytocics versus no treatment; </LI>
<LI>oxytocics and hormone therapy versus antibiotics; </LI>
<LI>oxytocics and hormone therapy versus placebo; </LI>
<LI>oxytocics and hormone therapy versus no treatment; </LI>
<LI>oxytocics, hormone therapy and antibiotics versus placebo; </LI>
<LI>oxytocics, hormone therapy and antibiotics versus no treatment; </LI>
<LI>hormone therapy versus placebo; </LI>
<LI>hormone therapy versus no treatment;</LI>
<LI>evacuation of retained products of conception versus each type of drug treatment;</LI>
<LI>evacuation of retained products of conception versus no treatment or placebo separately;</LI>
<LI>other surgical interventions separately versus each type of drug treatment;</LI>
<LI>other surgical interventions separately versus no treatment or placebo separately.</LI>
</UL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-02-12 14:10:32 +0000" MODIFIED_BY="Denise Atherton">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-02-12 14:10:44 +0000" MODIFIED_BY="Denise Atherton">
<P>(Subgroup analyses - <I>see</I> below - would have been limited to these.)</P>
<UL>
<LI>Cessation of abnormal vaginal bleeding (however determined by trialist) without need for further treatment;</LI>
<LI>serious maternal morbidity (as defined by trialist) or death;</LI>
<LI>blood transfusion(s);</LI>
<LI>hysterectomy;</LI>
<LI>evacuation of retained products (when this had not been the intervention);</LI>
<LI>additional treatments;</LI>
<LI>cessation of signs of infection (however determined by trialist).</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-02-12 14:10:49 +0000" MODIFIED_BY="Denise Atherton">
<UL>
<LI>Post-treatment ultrasound findings;</LI>
<LI>days in hospital as a result of secondary postpartum haemorrhage;</LI>
<LI>interval from randomisation to cessation of abnormal bleeding;</LI>
<LI>side-effects of treatment (for example, nausea, vomiting, hypertension, allergic reactions, uterine perforation);</LI>
<LI>economic outcomes;</LI>
<LI>women's level of satisfaction;</LI>
<LI>breast milk pharmacokinetics.</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-02-12 13:45:21 +0000" MODIFIED_BY="Denise Atherton">
<ELECTRONIC_SEARCHES MODIFIED="2008-02-12 13:44:16 +0000" MODIFIED_BY="Denise Atherton">
<P>We searched the Cochrane Pregnancy and Childbirth Group&#8217;s Trials Register by contacting the Trials Search Co-ordinator (31 January 2008).</P>
<P>The Cochrane Pregnancy and Childbirth Group&#8217;s Trials Register is maintained by the Trials Search Co-ordinator and contains trials identified from:</P>
<OL>
<LI>quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);</LI>
<LI>weekly searches of MEDLINE;</LI>
<LI>handsearches of 30 journals and the proceedings of major conferences;</LI>
<LI>weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts.</LI>
</OL>
<P>Details of the search strategies for CENTRAL and MEDLINE, the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service can be found in the &#8216;Specialized Register&#8217; section within the editorial information about the Cochrane Pregnancy and Childbirth Group.</P>
<P>Trials identified through the searching activities described above are given a code (or codes) depending on the topic. The codes are linked to review topics. The Trials Search Co-ordinator searches the register for each review using these codes rather than keywords.</P>
<P>We did not apply any language restrictions.</P>
</ELECTRONIC_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-02-12 14:33:26 +0000" MODIFIED_BY="Denise Atherton">
<P>The full papers of the 36 studies identified by the search strategy were considered against the 'selection criteria' independently by two of the authors blind to their authorship, journal of publication and results. We used a data extraction sheet. The third investigator acted as an advisor or arbitrator, or both. Where contact addresses were available, we wrote to the first named authors of the studies, requesting details of any further work that they knew of.</P>
<P>If any of the studies had met our inclusion criteria, we would have used the Review Manager software (<LINK REF="REF-RevMan-2000" TYPE="REFERENCE">RevMan 2000</LINK>) to enter the data and to check the accuracy of data entry. We would have also used the methods outlined in the Cochrane Handbook for Systematic Reviews of Interventions (<LINK REF="REF-Clarke-2000" TYPE="REFERENCE">Clarke 2000</LINK>). For full details of planned methods, <I>see</I> <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION MODIFIED="2008-02-14 13:56:16 +0000" MODIFIED_BY="Sonja Henderson">
<P>Of the 36 studies (47 papers) identified by the literature search, the seven papers identified from their reference lists and five identified following responses from first named authors, none were considered suitable for inclusion in the review. Details of the latter twelve papers are given in the 'Discussion' section below. None of the studies focused on the management of secondary postpartum haemorrhage and none mentioned excessive bleeding in the diagnostic criteria or definition of the condition being studied. It had been intended to include only studies of women between 24 hours and three months postdelivery; in the event, very few studies identified how long it was since the women had delivered.<BR/>
<BR/>Of the 36 studies identified by the literature review, nine concerned the management of endometritis following caesarean section, 15 the management of endometritis in general and 11 the prophylaxis of primary or secondary postpartum haemorrhage, endometritis, endocervicitis, and perineal infection. Of the 24 studies concerning the management of endometritis, 21 studied the use of antibiotics alone, one the use of cervical dilatation alone, one the use of antibiotics alone but with both groups also undergoing cervical dilatation and one the continued versus the non-continued use of antibiotics. One study was a comparison of uterotonic drugs for women of about three to five days postnatally, but solely to compare breast milk pharmacokinetics.<BR/>
<BR/>Of the 36 studies identified, 32 stated that allocation had been randomised, but for only 12 were some details of the randomisation process described. In the remaining four studies the allocation was quasi-random. For details of the excluded studies, <I>see</I> the 'Characteristics of excluded studies' table.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>No randomised trials were included.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>No randomised trials were included.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-02-14 13:42:04 +0000" MODIFIED_BY="Sonja Henderson">
<P>A letter was sent to the first named author of 33 of the 36 studies. A usable contact address was not available for the remaining three papers. A second letter/e-mail and letter were sent to the non-responders; eight replies were received.</P>
<P>Of the seven papers identified from the reference lists of the 36 studies, and the five identified following responses from first named authors, two were non-randomised trials of different oxytocic drugs for the management of the third stage of labour, five were case-study reports (three concerning secondary postpartum haemorrhage (PPH), one primary and secondary PPH and one primary PPH) and three were case series (one examining organisms causing endometritis; one its presenting symptoms and timing; and one the management of intractable primary PPH). One, translated, paper was a randomised comparison of uterotonic drugs for women at one to five days postpartum who had not needed 'oxytocic drugs'.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>No information is available from randomised controlled trials to inform the management of women with secondary postpartum haemorrhage.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>A well-designed randomised controlled trial comparing the various drug and surgical therapies for women with secondary postpartum haemorrhage against each other and against placebo or no treatment groups is needed. When devising exclusion criteria the severity of blood loss will need careful consideration.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We are grateful for the comments and encouragement that we received from Sally Marchant, Jo Garcia, Cathryn Glazener and Tim Hillard in relation to the original review. We would also like to thank the Consumer Panel for their valuable input.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known. </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Jo Alexander and Peter Thomas developed and wrote the protocol. Jo Alexander and Jill Sanghera identified relevant papers and reviewed them against the prespecified selection criteria. Peter Thomas arbitrated when consensus could not be reached. Jo Alexander, Peter Thomas and Jill Sanghera wrote the final review. Jill Sanghera was not a contributor to this update.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2008-02-14 13:43:38 +0000" MODIFIED_BY="Sonja Henderson">
<P>The title of the protocol which preceded this review was 'Drug treatment for secondary postpartum haemorrhage'. As the search terms used would also have identified any papers concerning surgical treatment, when the first named authors were written to, they were asked for details of any further work that they knew of concerning either drug or surgical treatments. This review therefore covers both.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2008-02-14 13:43:34 +0000" MODIFIED_BY="Sonja Henderson"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-02-12 14:22:21 +0000" MODIFIED_BY="Denise Atherton">
<STUDIES>
<INCLUDED_STUDIES/>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Andersen-1998" NAME="Andersen 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andersen B, Andersen L, Sorensen T</AU>
<TI>Methylergometrine during the early puerperium; a prospective randomized double blind study</TI>
<SO>Acta Obstetricia et Gynecologica Scandinavica</SO>
<YR>1998</YR>
<VL>77</VL>
<PG>54-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Andrinopoulos-1983" NAME="Andrinopoulos 1983" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andrinopoulos GC, Mendenhall HW</AU>
<TI>Prostaglandin F2 in the management of delayed postpartum hemorrhage</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1983</YR>
<VL>15</VL>
<PG>217-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Apuzzio-1985a" NAME="Apuzzio 1985a" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Apuzzio JJ, Ganesh V, Pelosi MA, Landau I, Kaminetzky HA, Kaminski Z et al. Comparative clinical evaluation of ceftizoxime with clindamycin and gentamicin and cefoxitin in the treatment of postcesarean endomyometritis . Surgery Gynecology and Obstetrics 1985;161:518-22.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Apuzzio JJ, Ganesh V, Pelosi MA, Landau I, Kaminetzky HA, Kaminski Z et al</AU>
<TI>Comparative clinical evaluation of ceftizoxime with clindamycin and gentamicin and cefoxitin in the treatment of postcesarean endomyometritis</TI>
<SO>Surgery, Gynecology and Obstetrics</SO>
<YR>1985</YR>
<VL>161</VL>
<PG>518-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Apuzzio-1985b" NAME="Apuzzio 1985b" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Apuzzio J, Kaminski Z, Gamesh V, Louria D</AU>
<TI>Comparative clinical evaluation of ticarcillin plus clavulanic acid versus clindamycin plus gentamicin in treatment of post-cesarean endomyometritis</TI>
<SO>American Journal of Medicine</SO>
<YR>1985</YR>
<VL>79</VL>
<PG>164-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arabin-1982" NAME="Arabin 1982" YEAR="8th E">
<REFERENCE NOTES="&lt;p&gt;Arabin B, Ruttgers H, Kubli F. Influence of a routine use of methergine on puerperal infection and breast feeding . Proceedings of 8th European Congress of Perinatal Medicine;1982; Brussels, Belgium, 1982:81.&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Arabin B, Ruttgers H, Kubli F</AU>
<TI>Influence of a routine use of methergine on puerperal infection and breast feeding</TI>
<SO>Proceedings of 8th European Congress of Perinatal Medicine; 1982 Sept 7-10; Brussels, Belgium</SO>
<YR>1982</YR>
<PG>81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arabin-1986" NAME="Arabin 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;Arabin B, Ruttgers H, Kubli F. Effects of routine administration of methylergometrin during the puerperium on involution, maternal morbidity, and lactation . Geburtshilfe und Frauenheilkunde 1986;46:215-20.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arabin B, Ruttgers H, Kubli F</AU>
<TI>Effects of routine administration of methylergometrin during the puerperium on involution, maternal morbidity, and lactation</TI>
<SO>Geburtshilfe und Frauenheilkunde</SO>
<YR>1986</YR>
<VL>46</VL>
<PG>215-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arredondo_x002d_Garcia" NAME="Arredondo-Garcia" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arrendondo-Garcia JL, Figueroa-Damian R, Ortiz-Ibarra FJ, Sosa-Gonzalez IA</AU>
<TI>Endometritis etiology:diagnosis and treatment. Experience of the Instituto Nacional de Perinatologia</TI>
<SO>Current Therapeutic Research</SO>
<YR>1993</YR>
<VL>54</VL>
<NO>5</NO>
<PG>529-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baumgarten-1983" NAME="Baumgarten 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;Baumgarten K, Schmidt J, Horvat A, Neumann M, Cerwenka R, Gruber W et al. Uterine motility after post-partum application of sulprostone and other oxytocics . European Journal of Obstetrics Gynecology and Reproductive Biology 1983;16:181-92.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baumgarten K, Schmidt J, Horvat A, Neumann M, Cerwenka R, Gruber W et al</AU>
<TI>Uterine motility after post-partum application of sulprostone and other oxytocics</TI>
<SO>European Journal of Obstetrics &amp; Gynecology and Reproductive Biology</SO>
<YR>1983</YR>
<VL>16</VL>
<PG>181-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bhattacharya-1988" NAME="Bhattacharya 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Bhattacharya P, Devi PK, Jain S, Kanthamani CR, Raghavan KS. Prophylactic use of 15(S)15 methyl PGF2alpha by intramuscular route for control of postpartum bleeding - a comparative trial with methylergometrine . Acta Obstetricia et Gynecologica Scandinavica Supplement 1988;145:13-5.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bhattacharya P, Devi PK, Jain S, Kanthamani CR, Raghavan KS</AU>
<TI>Prophylactic use of 15(S)15 methyl PGF2alpha by intramuscular route for control of postpartum bleeding - a comparative trial with methylergometrine</TI>
<SO>Acta Obstetricia et Gynecologica Scandinavica Supplement</SO>
<YR>1988</YR>
<VL>145</VL>
<PG>13-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bischoff-1956" NAME="Bischoff 1956" YEAR="1956">
<REFERENCE NOTES="&lt;p&gt;Bischoff P, Upchurch K, Carter J. The use of sulfisoxazole cream in the postpartum patient. American Journal of Obstetrics &amp;amp; Gynecology 1956;71:113-5.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bischoff P, Upchurch K, Carter J</AU>
<TI>The use of sulfisoxazole cream in the postpartum patient</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1956</YR>
<VL>71</VL>
<PG>113-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Briggs-1989" NAME="Briggs 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Briggs GG, Ambrose P, Nageotte MP. Gentamicin dosing in postpartum women with endometritis . American Journal of Obstetrics &amp;amp; Gynecology 1989;160:309-13.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Briggs GG, Ambrose P, Nageotte MP</AU>
<TI>Gentamicin dosing in postpartum women with endometritis</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1989</YR>
<VL>160</VL>
<PG>309-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cormier-1988" NAME="Cormier 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Cormier P, Leng JJ, Janky E, Brouste V, Duthil B. Antibiotic prophylaxis with cefotetan in the prevention of post-partum and post-abortum infectious complications in endo-uterine investigations . Revue Francaise de Gynecologie et d Obstetrique 1988;83:829-32.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cormier P, Leng JJ, Janky E, Brouste V, Duthil B</AU>
<TI>Antibiotic prophylaxis with cefotetan in the prevention of post-partum and post-abortum infectious complications in endo-uterine investigations</TI>
<SO>Revue Francaise de Gynecologie et d Obstetrique</SO>
<YR>1988</YR>
<VL>83</VL>
<PG>829-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Corson-1977" NAME="Corson 1977" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Corson SL, Bolognese RJ</AU>
<TI>Postpartum uterine atony treated with prostaglandins</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1977</YR>
<VL>129</VL>
<NO>8</NO>
<PG>918-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Del-Priore-1996" NAME="Del Priore 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Del Priore G, Jackson-stone M, Shim EK, Garfinkel J, Eichmann MA, Frederiksen MC. A Comparison of Once-Daily and 8-Hour Gentamicin Dosing in the Treatment of Postpartum Endometritis . Obstetrics &amp;amp; Gynecology 1996;87:994-1000.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Del Priore G, Jackson-Stone M, Shim EK, Garfinkel J, Eichmann MA, Frederiksen MC</AU>
<TI>A comparison of once-daily and 8-hour gentamicin dosing in the treatment of postpartum endometritis</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1996</YR>
<VL>87</VL>
<PG>994-1000</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dinsmoor-1991" NAME="Dinsmoor 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Dinsmoor MJ, Newton ER, Gibbs RS. A randomized, double-blind, placebo-controlled trial of oral antibiotic therapy following intravenous antibiotic therapy for postpartum endometritis . Obstetrics &amp;amp; Gynecology 1991;77:60-2.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dinsmoor MJ, Newton ER, Gibbs RS</AU>
<TI>A randomized, double-blind, placebo-controlled trial of oral antibiotic therapy following intravenous antibiotic therapy for postpartum endometritis</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1991</YR>
<VL>77</VL>
<PG>60-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Faro-1987" NAME="Faro 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;Faro S, Phillips LE, Baker JL, Goodrich KH, Turner RM, Riddle GD. Comparative efficacy and safety of mezlocillin, cefoxitin, and clindamycin plus gentamicin in postpartum endometritis . Obstetrics &amp;amp; Gynecology 1987;69:760-6.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Faro S, Phillips LE, Baker JL, Goodrich KH, Turner RM, Riddle GD</AU>
<TI>Comparative efficacy and safety of mezlocillin, cefoxitin, and clindamycin plus gentamicin in postpartum endometritis</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1987</YR>
<VL>69</VL>
<PG>760-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Faro-1988" NAME="Faro 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Faro S, Martens M, Phillips LE, Hamill H, Smith D, Riddle G. Ticarcillin disodium/clavulanate potassium vs clindamycin/gentamicin in the treatment of postpartum endometritis . Journal of Reproductive Medicine 1988;33:603-6.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Faro S, Martens M, Phillips LE, Hamill H, Smith D, Riddle G</AU>
<TI>Ticarcillin disodium/clavulanate potassium vs clindamycin/gentamicin in the treatment of postpartum endometritis</TI>
<SO>Journal of Reproductive Medicine</SO>
<YR>1988</YR>
<VL>33</VL>
<PG>603-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fernandez-1990" NAME="Fernandez 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Fernandez H, Claquin C, Guibert M, Papiernik E. Suspected postpartum endometritis: a controlled clinical trial of single-agent antibiotic therapy with amox-CA (augmentin R) vs ampicillin-metronidazole plus or minus aminoglycoside . European Journal of Obstetrics Gynecology and Reproductive Biology 1990;36:69-74.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fernandez H, Claquin C, Guibert M, Papiernik E</AU>
<TI>Suspected postpartum endometritis: a controlled clinical trial of single-agent antibiotic therapy with amox-CA (augmentin R) vs ampicillin-metronidazole plus or minus aminoglycoside</TI>
<SO>European Journal of Obstetrics &amp; Gynecology and Reproductive Biology</SO>
<YR>1990</YR>
<VL>36</VL>
<PG>69-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fernandez-1993" NAME="Fernandez 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Fernandez H, Gagnepain A, Bourget P, Peray P, Frydman R, Papiernik E et al. Antibiotic prophylaxis against postpartum endometritis after vaginal delivery: a prospective randomized comparison between Amox-CA (Augmentin) and abstention . European Journal of Obstetrics Gynecology and Reproductive Biology 1993;50:169-75.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fernandez H, Gagnepain A, Bourget P, Peray P, Frydman R, Papiernik E et al</AU>
<TI>Antibiotic prophylaxis against postpartum endometritis after vaginal delivery: a prospective randomized comparison between Amox-CA (Augmentin) and abstention</TI>
<SO>European Journal of Obstetrics &amp; Gynecology and Reproductive Biology</SO>
<YR>1993</YR>
<VL>50</VL>
<PG>169-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Figueroa_x002d_Damian-1992" NAME="Figueroa-Damian 1992" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Figueroa-Damian R, Angel-Muller E, Sosa-Gonzalez i, Arredondo-Garcia JL</AU>
<TI>Gyneco-obstetrical infections by anaerobic bacteria</TI>
<TO>Infecciones ginecoobstetricas por bacterias anaerobias</TO>
<SO>Ginecologia y Obstetricia de Mexico</SO>
<YR>1992</YR>
<VL>60</VL>
<PG>162-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Figueroa_x002d_Damian-1996" NAME="Figueroa-Damian 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Figueroa-Damian R, Villagrana-Zesati R, San Martin-Herrasti J, Arredondo-Garcia J. Comparison of therapeutic efficacy of piperacillin/tazobactam vs. ampicillin plus gentamicin in the treatment of post-cesarean endometritis [translation]. Ginecologia y Obstetricia de Mexico 1996;64:214-8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Figueroa-Damian R, Villagrana-Zesati R, San Martin-Herrasti J, Arredondo-Garcia J</AU>
<TI>Comparison of therapeutic efficacy of piperacillin/tazobactam vs. ampicillin plus gentamicin in the treatment of post-cesarean endometritis</TI>
<TO>Comparacion de la eficacia terapeutica de piperacilina/tazobactam vs ampicilina mas gentamicina en el tratamiento de endometritis poscesarea</TO>
<SO>Ginecologia y Obstetricia de Mexico</SO>
<YR>1996</YR>
<VL>64</VL>
<PG>214-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Friedman-1957" NAME="Friedman 1957" YEAR="1957">
<REFERENCE NOTES="&lt;p&gt;Friedman EA. Comparative clinical evaluation of postpartum oxytocics . American Journal of Obstetrics &amp;amp; Gynecology 1957;73:1306-13.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Friedman EA</AU>
<TI>Comparative clinical evaluation of postpartum oxytocics</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1957</YR>
<VL>73</VL>
<PG>1306-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gall-1996" NAME="Gall 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Gall S, Koukol DH. Ampicillin/sulbactam vs clindamycin/gentamicin in the treatment of postpartum endometritis . Journal of Reproductive Medicine 1996;41:575-80.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gall S, Koukol DH</AU>
<TI>Ampicillin/sulbactam vs clindamycin/gentamicin in the treatment of postpartum endometritis</TI>
<SO>Journal of Reproductive Medicine</SO>
<YR>1996</YR>
<VL>41</VL>
<PG>575-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gibbs-1988" NAME="Gibbs 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Gibbs RS, Dinsmoor MJ, Newton ER, Ramamurthy RS. A randomized trial of intrapartum vs immediate postpartum treatment of women with intra-amniotic infection . Obstetrics &amp;amp; Gynecology 1988;72:823-8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gibbs RS, Dinsmoor MJ, Newton ER, Ramamurthy RS</AU>
<TI>A randomized trial of intrapartum vs immediate postpartum treatment of women with intra-amniotic infection</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1988</YR>
<VL>72</VL>
<PG>823-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goldstein-1986" NAME="Goldstein 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goldstein AI, Kent DR, David A</AU>
<TI>Prostaglandin E2 vaginal suppositories in the treatment of intractable late-onset postpartum haemorrhage - a case report</TI>
<SO>Journal of Reproductive Medicine</SO>
<YR>1983</YR>
<VL>28</VL>
<NO>6</NO>
<PG>425-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greenberg-1987" NAME="Greenberg 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;Greenberg RN, Reilly PM, Weinandt WJ, Wilson KM, Bollinger M, Ojile JM. Comparison trial of clindamycin with aztreonam or gentamicin in the treatment of postpartum endometritis . Clinical Therapeutics 1987;10:36-9.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greenberg RN, Reilly PM, Weinandt WJ, Wilson KM, Bollinger M, Ojile JM</AU>
<TI>Comparison trial of clindamycin with aztreonam or gentamicin in the treatment of postpartum endometritis</TI>
<SO>Clinical Therapeutics</SO>
<YR>1987</YR>
<VL>10</VL>
<PG>36-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Groeber-1960" NAME="Groeber 1960" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Groeber WR, Bishop EH</AU>
<TI>Methergine and ergonovine in the third stage of labour</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1960</YR>
<VL>15</VL>
<NO>1</NO>
<PG>85-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grunberger-1983" NAME="Grunberger 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grunberger W</AU>
<TI>Postpartum uterus involution and lactation levels in randomized comparison between Prostin E2 tablets and Methergin-Dragees</TI>
<TO>Postpartale Uterusinvolution und Laktationsmengen im randomisierten Vergleich von Prostin-E2-Tabletten mit Methergin-Dragees</TO>
<SO>Gynakologische Rundschau</SO>
<YR>1983</YR>
<VL>23</VL>
<PG>100-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lancheros-1997" NAME="Lancheros 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lancheros S, Gaitan H</AU>
<TI>Comparison between two therapeutic schedules: gentamicin plus gentamicyn and pefloxacin plus metronidazol in post-cesarean endometritis treatment. A clinical trial</TI>
<SO>Acta Obstetricia et Gynecologica Scandinavica</SO>
<YR>1997</YR>
<VL>76</VL>
<PG>28</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ledee-2001" NAME="Ledee 2001" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ledee N, Ville Y, Musset D, Mercier F, Frydman R, Fernandez H</AU>
<TI>Management in intractable obstetric haemorrhage: an audit on 61 cases</TI>
<SO>European Journal of Obstetrics &amp; Gynecology and Reproductive Biology</SO>
<YR>2001</YR>
<VL>94</VL>
<NO>2</NO>
<PG>189-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maccato-1991" NAME="Maccato 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Maccato ML, Faro S, Martens MG, Hammill HA. Ciprofloxacin vs gentamicin/clindamycin for postpartum endometritis . Journal of Reproductive Medicine 1991;36:857-61.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maccato ML, Faro S, Martens MG, Hammill HA</AU>
<TI>Ciprofloxacin vs gentamicin/clindamycin for postpartum endometritis</TI>
<SO>Journal of Reproductive Medicine</SO>
<YR>1991</YR>
<VL>36</VL>
<PG>857-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martens-1989" NAME="Martens 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Martens MG, Faro S, Hammill HA, Maccato M, Riddle G, Smith D. Ampicillin/sulbactam vs clindamycin in the treatment of postpartum endomyometritis . Southern Medical Journal 1989;82:39.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martens MG, Faro S, Hammill HA, Maccato M, Riddle G, Smith D</AU>
<TI>Ampicillin/sulbactam vs clindamycin in the treatment of postpartum endomyometritis</TI>
<SO>Southern Medical Journal</SO>
<YR>1989</YR>
<VL>82</VL>
<PG>39</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McGregor-1989" NAME="McGregor 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;McGregor JA, Christensen FB. A comparison of ampicillin plus sulbactam vs clindamycin and gentamicin for treatment of postpartum infection . International Journal of Gynecology and Obstetrics 1989;S2:35-9.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McGregor JA, Christensen FB</AU>
<TI>A comparison of ampicillin plus sulbactam vs clindamycin and gentamicin for treatment of postpartum infection</TI>
<SO>International Journal of Gynecology &amp; Obstetrics</SO>
<YR>1989</YR>
<VL>S2</VL>
<PG>35-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mitra-1997" NAME="Mitra 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Mitra A, Whitten K, Laurent S, Anderson W. A randomized, prospective study comparing once-daily gentamicin versus thrice-daily gentamicin in the treatment of puerperal infection. American Journal of Obstetrics &amp;amp; Gynecology 1997;177:786-92.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mitra A, Whitten K, Laurent S, Anderson W</AU>
<TI>A randomized, prospective study comparing once-daily gentamicin versus thrice-daily gentamicin in the treatment of puerperal infection</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1997</YR>
<VL>177</VL>
<PG>786-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moodie-1976" NAME="Moodie 1976" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moodie JE, Moir DD</AU>
<TI>Ergometrine, oxytocin and extradural analgesia</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>1976</YR>
<VL>48</VL>
<PG>571</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morales-1989" NAME="Morales 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Morales WJ, Collins EM, Angel JL, Knuppel RA. Short course of antibiotic therapy in treatment of postpartum endomyometritis . American Journal of Obstetrics &amp;amp; Gynecology 1989;161:568-72.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morales WJ, Collins EM, Angel JL, Knuppel RA</AU>
<TI>Short course of antibiotic therapy in treatment of postpartum endomyometritis</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1989</YR>
<VL>161</VL>
<PG>568-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Paraskevaides-1993" NAME="Paraskevaides 1993" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Paraskevaides E, Stuart B, Gardeil F</AU>
<TI>Secondary postpartum haemorrhage from nondehisced lower caesarean section scar: a case for hysteroscopy</TI>
<SO>Australian and New Zealand Journal of Obstetrics and Gynaecology</SO>
<YR>1993</YR>
<VL>33</VL>
<NO>4</NO>
<PG>427</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Perry-1997" NAME="Perry 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Perry K, Theilman G, Coker K, Martin J. A prospective randomized trial comparing Gentamicin administered every 8 hours versus Gentamicin administered every 24 hours for the treatment of postcesarean section endometritis. American Journal of Obstetrics &amp;amp; Gynecology 1997;176:S59.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perry K, Theilman G, Coker K, Martin J</AU>
<TI>A prospective randomized trial comparing Gentamicin administered every 8 hours versus Gentamicin administered every 24 hours for the treatment of postcesarean section endometritis</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1997</YR>
<VL>176</VL>
<PG>S59</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pond-1979" NAME="Pond 1979" YEAR="1979">
<REFERENCE NOTES="&lt;p&gt;Pond DG, Bernstein EP, Love KR, Morgan JR, Velland H, Smith JA. Comparison of ampicillin with clindamycin plus gentamicin in the treatment of postpartum uterine infection . Canadian Medical Association Journal 1979;120:533-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pond DG, Bernstein EP, Love KR, Morgan JR, Velland H, Smith JA</AU>
<TI>Comparison of ampicillin with clindamycin plus gentamicin in the treatment of postpartum uterine infection</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>1979</YR>
<VL>120</VL>
<PG>533-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rodriguez_x002d_Ballestero" NAME="Rodriguez-Ballestero" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Rodriguez-Ballesteros R, Alarcon-Aburto V, De Los Angeles Madrigal-De La Campa M, Valerio-Castro E. Antibiotics short course in post-cesarean endometritis treatment (translation). Ginecologia y Obstetricia de Mexico 1996;64:359-62.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rodriguez-Ballesteros R, Alarcon-Aburto V, De Los Angeles Madrigal-De La Campa M, Valerio-Castro E</AU>
<TI>Antibiotics short course in post-cesarean endometritis treatment</TI>
<TO>Esquema corto de antibioticos en el tratamiento de endometritis posterior a cesarea</TO>
<SO>Ginecologia y Obstetricia de Mexico</SO>
<YR>1996</YR>
<VL>64</VL>
<PG>359-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rubin-1961" NAME="Rubin 1961" YEAR="1961">
<REFERENCE NOTES="&lt;p&gt;Rubin A. Use of a sulfonamide vaginal cream post partum. A controlled 'blind' study of 700 patients. American Journal of Obstetrics &amp;amp; Gynecology 1961;82:860-2.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rubin A</AU>
<TI>Use of a sulfonamide vaginal cream post partum. A controlled 'blind' study of 700 patients</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1961</YR>
<VL>82</VL>
<PG>860-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sen-1980" NAME="Sen 1980" YEAR="1980">
<REFERENCE NOTES="&lt;p&gt;Sen P, Apuzzio J, Reyelt C, Kaminski T, Levy F, Kapila R et al. Prospective evaluation of combinations of antimicrobial agents for endometritis after cesarean section. Surgery Gynecology and Obstetrics 1980;151:89-92.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sen P, Apuzzio J, Reyelt C, Kaminski T, Levy F, Kapila R et al</AU>
<TI>Prospective evaluation of combinations of antimicrobial agents for endometritis after cesarean section</TI>
<SO>Surgery, Gynecology and Obstetrics</SO>
<YR>1980</YR>
<VL>151</VL>
<PG>89-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sorrell-1981" NAME="Sorrell 1981" YEAR="1981">
<REFERENCE NOTES="&lt;p&gt;Sorrell TC, Marshall JR, Yoshimori R, Chow AW. Antimicrobial therapy of postpartum endomyometritis. II. Prospective randomized trial of mezlocillin vs ampicillin. American Journal of Obstetrics &amp;amp; Gynecology 1981;141:246-51.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sorrell TC, Marshall JR, Yoshimori R, Chow AW</AU>
<TI>Antimicrobial therapy of postpartum endomyometritis. II. Prospective randomized trial of mezlocillin vs ampicillin</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1981</YR>
<VL>141</VL>
<PG>246-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Takagi-1976" NAME="Takagi 1976" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Takagi S, Yoshida T, Togo Y, Tochigi H, Abe M, Sakata H et al</AU>
<TI>The effects of intramyometrial injection of prostaglandin F2 on severe postpartum haemorrhage</TI>
<SO>Prostaglandins</SO>
<YR>1976</YR>
<VL>12</VL>
<NO>4</NO>
<PG>565-79</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vogel-2004" NAME="Vogel 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;Vogel D, Burkhardt T, Rentsch K, Schweer H, Watzer B, Zimmerman R et al. Misoprostol versus methylergometrine: pharmacokinetics in human milk . American Journal of Obstetrics and Gynecology 2004;191:2168-73&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vogel D, Burkhardt T, Rentsch K, Schweer H, Watzer B, Zimmerman R et al</AU>
<TI>Misoprostol versus methylergometrine: pharmacokinetics in human milk</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2004</YR>
<VL>191</VL>
<PG>2168-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Walss_x002d_Rodriguez-1990" NAME="Walss-Rodriguez 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Walss-Rodriguez RJ, Rocha-Avila LC. Puerperal deciduometritis. Importance of mechanical cervical dilatation (translation). Ginecologia y Obstetricia de Mexico 1990;58:270-3.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Walss-Rodriguez RJ, Rocha-Avila LC</AU>
<TI>Puerperal deciduometritis. Importance of mechanical cervical dilatation</TI>
<SO>Ginecologia y Obstetricia de Mexico</SO>
<YR>1990</YR>
<VL>58</VL>
<PG>270-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Whitten-1997" NAME="Whitten 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Whitten K, Mitra A, Laurent S, Anderson B. A randomized, prospective study comparing once daily Gentamicin with thrice daily Gentamicin in the treatment of puerperal endometritis. American Journal of Obstetrics &amp;amp; Gynecology 1997;176:S32.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Whitten K, Mitra A, Laurent S, Anderson B</AU>
<TI>A randomized, prospective study comparing once daily Gentamicin with thrice daily Gentamicin in the treatment of puerperal endometritis</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1997</YR>
<VL>176</VL>
<PG>S32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-02-12 14:22:21 +0000" MODIFIED_BY="Denise Atherton">
<ADDITIONAL_REFERENCES MODIFIED="2008-02-12 14:22:21 +0000" MODIFIED_BY="Denise Atherton">
<REFERENCE ID="REF-ACOG-1990" NAME="ACOG 1990" TYPE="JOURNAL_ARTICLE">
<AU>American College of Obstetrics and Gynecology</AU>
<TI>Diagnosis and management of postpartum haemorrhage</TI>
<SO>International Journal of Gynecology &amp; Obstetrics</SO>
<YR>1990</YR>
<VL>36</VL>
<PG>159-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Alexander-1997" NAME="Alexander 1997" TYPE="BOOK">
<AU>Alexander J, Garcia J, Marchant S</AU>
<TI>The BLiPP Study - a survey and case control study</TI>
<SO>Final report to the South and West NHS Executive Research and Development Committee (Response mode)</SO>
<YR>1997</YR>
<PB>Institute of Health and Community Studies. Bournemouth University</PB>
<CY>Bournemouth</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="ISBN 1-85899-094-7"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Begley-1990" NAME="Begley 1990" TYPE="JOURNAL_ARTICLE">
<AU>Begley CM</AU>
<TI>A comparison of 'active' and 'physiological' management of the third stage of labour</TI>
<SO>Midwifery</SO>
<YR>1990</YR>
<VL>6</VL>
<PG>3-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bick-1995" NAME="Bick 1995" TYPE="JOURNAL_ARTICLE">
<AU>Bick DE, MacArthur C</AU>
<TI>The extent, severity and effect of health problems after childbirth</TI>
<SO>British Journal of Midwifery</SO>
<YR>1995</YR>
<VL>3</VL>
<NO>1</NO>
<PG>27-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Calhoun-1995" NAME="Calhoun 1995" TYPE="JOURNAL_ARTICLE">
<AU>Calhoun BC, Brost B</AU>
<TI>Emergency management of sudden puerperal fever</TI>
<SO>Obstetrics and Gynecology Clinics of North America</SO>
<YR>1995</YR>
<VL>22</VL>
<NO>2</NO>
<PG>357-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CEMACH-2004" NAME="CEMACH 2004" TYPE="BOOK">
<AU>Confidential Enquiry into Maternal and Child Health</AU>
<SO>Why mothers die 2000-2002. The sixth report of the Confidential Enquiries into Maternal Deaths in the United Kingdom</SO>
<YR>2004</YR>
<PB>RCOG Press</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clarke-2000" NAME="Clarke 2000" TYPE="OTHER">
<AU>Clarke M, Oxman AD, editors</AU>
<TI>Cochrane Reviewers&#8217; Handbook 4.1.1 [updated December 2000]</TI>
<SO>In: The Cochrane Library [database on CDROM]. The Cochrane Collaboration. Oxford: Update Software 2001, Issue 2</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Crowley-1984" NAME="Crowley 1984" TYPE="JOURNAL_ARTICLE">
<AU>Crowley J</AU>
<TI>Post-delivery bleeding due to group B beta-haemolytic streptococcal infection</TI>
<SO>New Zealand Medical Journal</SO>
<YR>1984</YR>
<VL>97</VL>
<PG>377</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dewhurst-1966" NAME="Dewhurst 1966" TYPE="JOURNAL_ARTICLE">
<AU>Dewhurst CJ</AU>
<TI>Secondary postpartum haemorrhage</TI>
<SO>Journal of Obstetrics &amp; Gynaecology of the British Commonwealth</SO>
<YR>1966</YR>
<VL>73</VL>
<PG>53-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DoH-1999" NAME="DoH 1999" TYPE="BOOK">
<AU>Department of Health</AU>
<SO>Why mothers die - report on confidential enquiries into maternal deaths in the United Kingdom 1994-1996</SO>
<YR>1999</YR>
<PB>Department of Health</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-French-2004" MODIFIED="2008-02-12 14:22:21 +0000" MODIFIED_BY="Denise Atherton" NAME="French 2004" NOTES="&lt;p&gt;This record should be cited as: French LM, Smaill FM. Antibiotic regimens for endometritis after delivery. Cochrane Database of Systematic Reviews 2004, Issue 4&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-02-12 14:22:21 +0000" NOTES_MODIFIED_BY="Denise Atherton" TYPE="COCHRANE_REVIEW">
<AU>French LM, Smaill FM</AU>
<TI>Antibiotic regimens for endometritis after delivery</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-02-12 14:22:21 +0000" MODIFIED_BY="Denise Atherton">
<IDENTIFIER MODIFIED="2008-02-12 14:22:21 +0000" MODIFIED_BY="Denise Atherton" TYPE="DOI" VALUE="10.1002/14651858.CD001067.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Glazener-1995" NAME="Glazener 1995" TYPE="JOURNAL_ARTICLE">
<AU>Glazener CMA, Abdalla M, Stroud P, Naji S, Templeton A, Russel IT</AU>
<TI>Postnatal maternal morbidity: extent, causes, prevention and treatment</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1995</YR>
<VL>102</VL>
<PG>282-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Glazener-1999" NAME="Glazener 1999" TYPE="BOOK">
<AU>Glazener CMA</AU>
<SO>Investigation of postnatal experience and care in Grampian [Unpublished PhD thesis]</SO>
<YR>1999</YR>
<PB>University of Aberdeen</PB>
<CY>Aberdeen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-King-1989" NAME="King 1989" TYPE="JOURNAL_ARTICLE">
<AU>King PA, Duthie SJ, Dong ZG, Ma HK</AU>
<TI>Secondary postpartum haemorrhage</TI>
<SO>Australian and New Zealand Journal of Obstetrics and Gynaecology</SO>
<YR>1989</YR>
<VL>29</VL>
<NO>4</NO>
<PG>394-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lester-1956" NAME="Lester 1956" TYPE="JOURNAL_ARTICLE">
<AU>Lester WM, Bartholomew RA, Colvin ED, Grimes WH, Fish JS, Galloway WH</AU>
<TI>The role of retained placental fragments in immediate and delayed postpartum hemorrhage</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1956</YR>
<VL>72</VL>
<NO>6</NO>
<PG>1214-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-MacArthur-1991" NAME="MacArthur 1991" TYPE="BOOK">
<AU>MacArthur C, Lewis M, Knox EG</AU>
<SO>Health after childbirth</SO>
<YR>1991</YR>
<PB>HMSO</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marchant-2006" NAME="Marchant 2006" TYPE="JOURNAL_ARTICLE">
<AU>Marchant S, Alexander J, Thomas P, Garcia J, Brocklehurst P, Keene J</AU>
<TI>Risk factors for hospital admission related to excessive and/or prolonged postpartum vaginal blood loss after the first 24 h following childbirth</TI>
<SO>Paediatric and Perinatal Epidemiology</SO>
<YR>2006</YR>
<VL>20</VL>
<PG>392-402</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Milligan-1992" NAME="Milligan 1992" TYPE="JOURNAL_ARTICLE">
<AU>Milligan DA, Brady K, Duff P</AU>
<TI>Short-term parenteral antibiotic therapy for puerperal endometritis</TI>
<SO>Journal of Maternal-Fetal Medicine</SO>
<YR>1992</YR>
<VL>1</VL>
<PG>60-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Novak_x002d_Antolic-1997" NAME="Novak-Antolic 1997" TYPE="JOURNAL_ARTICLE">
<AU>Novak-Antolic Z, Pajntar M, Verdenik I</AU>
<TI>Rupture of the membranes and postpartum infection</TI>
<SO>European Journal of Obstetrics &amp; Gynecology and Reproductive Biology</SO>
<YR>1997</YR>
<VL>71</VL>
<PG>141-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Raphael_x002d_Leff-1991" NAME="Raphael-Leff 1991" TYPE="BOOK">
<AU>Raphael-Leff J</AU>
<SO>Psychological processes of childbearing</SO>
<YR>1991</YR>
<PB>Chapman and Hall</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RCOG-1994" NAME="RCOG 1994" TYPE="BOOK">
<AU>Royal College of Obstetricians and Gynaecologists</AU>
<SO>Bleeding after childbirth</SO>
<YR>1994</YR>
<PB>RCOG</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2000" NAME="RevMan 2000" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2000</YR>
<EN>4.1 for Windows</EN>
<PB>The Cochrane Collaboration</PB>
<CY>Oxford, England</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rome-1975" NAME="Rome 1975" TYPE="JOURNAL_ARTICLE">
<AU>Rome RM</AU>
<TI>Secondary postpartum haemorrhage</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1975</YR>
<VL>82</VL>
<PG>289-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stovall-1998" NAME="Stovall 1998" TYPE="JOURNAL_ARTICLE">
<AU>Stovall TG, Ambrose SE, Ling FW, Anderson GD</AU>
<TI>Short-course antibiotic therapy for the treatment of chorioamnionitis and postpartum endomyometritis</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1998</YR>
<VL>159</VL>
<NO>2</NO>
<PG>404-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thorsteinsson-1970" NAME="Thorsteinsson 1970" TYPE="JOURNAL_ARTICLE">
<AU>Thorsteinsson VT, Kempers RD</AU>
<TI>Delayed postpartum bleeding</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1970</YR>
<VL>107</VL>
<NO>4</NO>
<PG>565-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weisenberg_x002d_Smith1993" NAME="Weisenberg-Smith1993" TYPE="UNPUBLISHED">
<AU>Weisenberg-Smith S</AU>
<TI>Literature review of secondary postpartum bleeding</TI>
<SO>National Perinatal Epidemiology Unit, Oxford, Unpublished</SO>
<YR>1993</YR>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Andersen-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not concerning treatment of secondary postpartum haemorrhage.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Andrinopoulos-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case study report, not a RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Apuzzio-1985a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not concerning treatment of secondary postpartum haemorrhage.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Apuzzio-1985b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not concerning treatment of secondary postpartum haemorrhage.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Arabin-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not concerning treatment of secondary postpartum haemorrhage.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Arabin-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not concerning treatment of secondary postpartum haemorrhage.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Arredondo_x002d_Garcia">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not concerning treatment of secondary postpartum haemorrhage.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Baumgarten-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not concerning treatment of secondary postpartum haemorrhage.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bhattacharya-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not concerning treatment of secondary postpartum haemorrhage.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bischoff-1956">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not concerning treatment of secondary postpartum haemorrhage.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Briggs-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not concerning treatment of secondary postpartum haemorrhage.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cormier-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not concerning treatment of secondary postpartum haemorrhage.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Corson-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not concerning treatment of secondary postpartum haemorrhage.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Del-Priore-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not concerning treatment of secondary postpartum haemorrhage.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dinsmoor-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not concerning treatment of secondary postpartum haemorrhage.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Faro-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not concerning treatment of secondary postpartum haemorrhage.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Faro-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not concerning treatment of secondary postpartum haemorrhage.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fernandez-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not concerning treatment of secondary postpartum haemorrhage.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fernandez-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not concerning treatment of secondary postpartum haemorrhage.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Figueroa_x002d_Damian-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not concerning treatment of secondary postpartum haemorrhage.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Figueroa_x002d_Damian-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not concerning treatment of secondary postpartum haemorrhage.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Friedman-1957">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not concerning treatment of secondary postpartum haemorrhage.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gall-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not concerning treatment of secondary postpartum haemorrhage.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gibbs-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not concerning treatment of secondary postpartum haemorrhage.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Goldstein-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case study report, not a RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Greenberg-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not concerning treatment of secondary postpartum haemorrhage.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Groeber-1960">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not concerning treatment of secondary postpartum haemorrhage.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Grunberger-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not apparently concerning treatment of secondary postpartum haemorrhage.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lancheros-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not concerning treatment of secondary postpartum haemorrhage.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ledee-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Concerning treatment of both primary and secondary postpartum haemorrhage. Audit of 61 case studies.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Maccato-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not concerning treatment of secondary postpartum haemorrhage.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Martens-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not concerning treatment of secondary postpartum haemorrhage.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McGregor-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not concerning treatment of secondary postpartum haemorrhage.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mitra-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not concerning treatment of secondary postpartum haemorrhage.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Moodie-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not concerning treatment of secondary postpartum haemorrhage.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Morales-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not concerning treatment of secondary postpartum haemorrhage.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Paraskevaides-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case study report, not a RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Perry-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not concerning treatment of secondary postpartum haemorrhage.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pond-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not concerning treatment of secondary postpartum haemorrhage.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rodriguez_x002d_Ballestero">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not concerning treatment of secondary postpartum haemorrhage.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rubin-1961">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not concerning treatment of secondary postpartum haemorrhage.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sen-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not concerning treatment of secondary postpartum haemorrhage.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sorrell-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not concerning treatment of secondary postpartum haemorrhage.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Takagi-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>Concerning treatment of both primary and secondary postpartum haemorrhage. Case study report, not a RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vogel-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not apparently concerning treatment of secondary postpartum haemorrhage.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Walss_x002d_Rodriguez-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not concerning treatment of secondary postpartum haemorrhage.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Whitten-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not concerning treatment of secondary postpartum haemorrhage.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>RCT = randomised controlled trial</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-02-12 14:33:35 +0000" MODIFIED_BY="Denise Atherton"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-02-14 13:50:47 +0000" MODIFIED_BY="Sonja Henderson">
<APPENDIX ID="APP-01" MODIFIED="2008-02-14 13:50:47 +0000" MODIFIED_BY="Sonja Henderson" NO="1">
<TITLE MODIFIED="2008-02-12 14:32:45 +0000" MODIFIED_BY="Denise Atherton">Planned methods</TITLE>
<APPENDIX_BODY MODIFIED="2008-02-14 13:50:47 +0000" MODIFIED_BY="Sonja Henderson">
<SUBSECTION>
<HEADING LEVEL="3">Sifting studies</HEADING>
<P>This will be carried out by the Contact person and a co-author independently and blind to authorship. The abstracts of all identified studies will be assessed against the 'Selection criteria'. Those that obviously do not satisfy them will be discarded. The remainder will be retrieved in full and their eligibility assessed without consideration of their results. Disagreements will be resolved by discussion between two authors and, if necessary, with the third author. If disagreement persists, we will seek a final decision from the Topic Editor.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Critical appraisal of studies</HEADING>
<P>Both authors will assess all trials for methodological quality independently. Quality of allocation concealment will be assessed using scores A (adequate concealment), B (uncertainty about adequacy of concealment) and C (not adequately concealed) as described in the Cochrane Handbook for Systematic Reviews of Interventions (<LINK REF="REF-Clarke-2000" TYPE="REFERENCE">Clarke 2000</LINK>). All trials will be included in the primary analyses regardless of score. Quality will be taken into account in a sensitivity analysis where the robustness of the results will be tested by removing the lower quality studies.</P>
<P/>
<P>Since there is the potential for blinding of allocation in these trials, we will also score trials according to whether they were double-blinded (0 = no, 1 = yes but only stated, 2 = yes described and appropriate), and we will identify those trials which did not provide a description of withdrawals and dropouts. These quality assessments will be used for descriptive purposes, and to inform further sensitivity analyses.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data extraction</HEADING>
<P>Two authors will independently extract data for each eligible trial. The data will be entered on printed data sheets with prespecified outcomes. Completed data sheets will be compared and any discrepancies resolved before analysis. If agreement cannot be reached, we will seek a final decision from the Topic Editor.</P>
<P>Any data that do not fit the outcomes prespecified by the authors will be collected, clearly labelled as 'not prespecified' and reported. In order to minimise the risk of bias, we plan to base our conclusions on the prespecified outcomes only. Data needed for subgroup analysis will also be collected.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Analysis</HEADING>
<P>All primary outcomes are dichotomous, and will be compared individually between the (potentially) 20 drug treatment and control group combinations. The effect of each treatment on each outcome in each study will be summarised by odds ratios and 95% confidence intervals. Results will be displayed graphically. Heterogeneity between studies for each particular treatment or control group combination and particular outcome will be tested using a chi-squared test. If not significant, a fixed-effect model will be assumed, and the results from the studies pooled using the Mantel-Haenszel method. If significant, we will assess whether variation between studies can be explained by differences in methodological quality, or (cautiously, because of interpretational difficulties in comparing non-randomised groups) differences in population or intervention. The use of a random-effects model will also be considered.<BR/>
<BR/>Of interest will be whether there is heterogeneity between studies investigating treatment and placebo compared with treatment and no treatment, for each of the types of treatment. If there is no evidence of heterogeneity, we will also take a broader view and conduct an additional meta-analysis combining the placebo controlled and 'no treatment' controlled studies. A similar approach will be taken for studies investigating the effect of hormone therapy; if there is evidence of heterogeneity between studies using oestrogen therapy and those using progesterone therapy, then separate meta-analyses will be conducted.<BR/>
<BR/>If there are sufficient studies, funnel plots will be used to assess the risk of publication bias.<BR/>
<BR/>A 5% level of statistical significance will be used throughout. It is recognised that there are potentially a large amount of significance tests to be done, and accordingly an increased chance of type I errors. Interpretation of results will be done cautiously, particularly where P values are greater than 0.01 or results are inconsistent, or both.<BR/>
<BR/>A number of formal subgroup analyses will be done. Greater interpretational weight will be given to subgroups identifiable within studies rather than between studies (where interpretation is much less reliable). Parity (primiparae versus multiparae), whether rupture of membranes had occurred prior to the onset of labour or not, the type of delivery (normal vaginal; vaginal operative including breech; caesarean section) and whether the placenta or membranes, or both, were complete will be included in the subgroup analysis. Specific tests of the treatment x subgroup interactions (using logistic regression) will be carried out to aid proper interpretation of the subgroup analysis.<BR/>
<BR/>We will conduct sensitivity analyses to assess the robustness of the results. This may involve the removal of smaller studies (publication bias), or studies of relatively poor methodological quality, or both. It may also include assessment of publication bias, or other types of bias by looking at robustness of the results under various scenarios that assume certain levels of bias.</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>